LataMed AI Corp. (OTC: LMEDD) announced that its previously announced 5-for-1 forward stock split became effective at the opening of trading on July 15, 2026, following publication on the FINRA Daily List. The company's common stock will trade under the temporary symbol LMEDD for approximately 20 business days before reverting to LMED, with a new CUSIP number 21116R404 replacing the prior number 21116R305.
Forward stock splits are typically executed to increase the number of outstanding shares and reduce the per-share price, potentially improving liquidity and making shares more accessible to a broader range of investors. For LataMed AI, a development-stage digital health and AI company, this corporate action aligns with its stated focus on expanding its telemedicine platform and pursuing commercialization opportunities for its artificial intelligence platforms, including CardioAI, PulmoAI, and NeuroAI.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., emphasized the significance of the split, stating: “Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms.”
The company clarified that shareholders holding shares through brokerage accounts or in electronic book-entry form generally do not need to take any action, as brokerage firms and custodians will process the split automatically. Physical certificate holders are not required to surrender their certificates immediately but will receive post-split shares under the new CUSIP when they present them for transfer, sale, or exchange.
This stock split comes as LataMed AI continues to build its presence in emerging markets, particularly Latin America, with a focus on telehealth infrastructure, healthcare coordination tools, and AI-enabled solutions. The company's strategy centers on developing technology platforms to support healthcare access, patient engagement, provider coordination, emergency medical response, pharmacy integration, insurance accessibility, payment solutions, and data-driven operations.
For investors, the forward split may indicate management's confidence in the company's growth trajectory and its efforts to position the stock for broader market participation. However, LataMed AI remains a development-stage company with significant risks, including the need for additional financing, regulatory approvals, and successful commercialization of its platforms. The company's filings with the U.S. Securities and Exchange Commission at www.sec.gov provide detailed risk factors.
The temporary "D" designation in the trading symbol is a standard FINRA identifier for corporate actions and will remain for about 20 business days. The company encourages shareholders with questions to contact their brokerage firm or its transfer agent. Additional information is available at https://latamed.ai.
This corporate action underscores LataMed AI's commitment to advancing its AI-driven healthcare solutions, with potential implications for the digital health industry as the company seeks to scale its operations and deliver innovative tools for emerging markets. The forward split may also signal a step toward potential uplisting or increased institutional interest, though the company's success ultimately hinges on its ability to execute its business plan and generate revenue from its AI platforms.
